Serum levels of insulin-like growth factor binding proteins in Ecuadorean children with growth hormone insensitivity.
Although insulin-like growth factor binding proteins (IGFBPs) are known to be important modulators of the action of insulin-like growth factors (IGFs), regulation of their production in vivo is not completely understood. Serum concentrations of IGFBP-3, -4 and -5 and acid-labile subunit (ALS) were therefore examined in 20 children with growth hormone (GH) insensitivity before and after 6 months of therapy with recombinant human IGF-I (80 or 120 micrograms/kg twice daily). The IGFBP concentrations in these children were compared with those in 62 GH-deficient children receiving GH therapy for 3 months. Serum levels of IGFBP-3, -4 and -5 and ALS all increased significantly (p < 0.0001) in GH-deficient children in response to GH therapy, whereas no significant increases occurred in the children with GH insensitivity. These findings indicate that GH is responsible for the regulation of serum levels of IGFBP-3, -4 and -5 and ALS, and that IGF-I does not directly regulate the concentrations of these circulating IGFBPs.
Burren
C P
CP
Department of Pediatrics, Oregon Health Sciences University, Portland 97210, USA.
Wanek
D
D
Mohan
S
S
Cohen
P
P
Guevara-Aguirre
J
J
Rosenfeld
R G
RG
D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004484:Ecuador; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood* / Q000187:drug effects; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008297:Male; D011863:Radioimmunoassay; D011986:Receptors, Somatotropin / Q000235:genetics*; D012016:Reference Values; D013577:Syndrome
D018969:Insulin-Like Growth Factor Binding Proteins; D011986:Receptors, Somatotropin; D007334:Insulin-Like Growth Factor I